HRP20110599T1 - Antitijela protiv toksina clostridium difficile i njihove primjene - Google Patents
Antitijela protiv toksina clostridium difficile i njihove primjene Download PDFInfo
- Publication number
- HRP20110599T1 HRP20110599T1 HR20110599T HRP20110599T HRP20110599T1 HR P20110599 T1 HRP20110599 T1 HR P20110599T1 HR 20110599 T HR20110599 T HR 20110599T HR P20110599 T HRP20110599 T HR P20110599T HR P20110599 T1 HRP20110599 T1 HR P20110599T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- antigen
- seq
- nos
- variable region
- Prior art date
Links
- 241000193163 Clostridioides difficile Species 0.000 title claims abstract 14
- 239000003053 toxin Substances 0.000 title 1
- 231100000765 toxin Toxicity 0.000 title 1
- 108700012359 toxins Proteins 0.000 title 1
- 239000000427 antigen Substances 0.000 claims abstract 31
- 108091007433 antigens Proteins 0.000 claims abstract 31
- 102000036639 antigens Human genes 0.000 claims abstract 31
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims abstract 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 11
- 101710084578 Short neurotoxin 1 Proteins 0.000 claims abstract 2
- 101710182532 Toxin a Proteins 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims 13
- 101710182223 Toxin B Proteins 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 241001465754 Metazoa Species 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 239000006041 probiotic Substances 0.000 claims 2
- 230000000529 probiotic effect Effects 0.000 claims 2
- 235000018291 probiotics Nutrition 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108010001478 Bacitracin Proteins 0.000 claims 1
- 108010059993 Vancomycin Proteins 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229960003071 bacitracin Drugs 0.000 claims 1
- 229930184125 bacitracin Natural products 0.000 claims 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 claims 1
- 230000001268 conjugating effect Effects 0.000 claims 1
- 238000002405 diagnostic procedure Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 108010074605 gamma-Globulins Proteins 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims 1
- 229960000282 metronidazole Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 229960002181 saccharomyces boulardii Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229940031572 toxoid vaccine Drugs 0.000 claims 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims 1
- 229960003165 vancomycin Drugs 0.000 claims 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims 1
- -1 wherein the antibody Proteins 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54235704P | 2004-02-06 | 2004-02-06 | |
| US61385404P | 2004-09-28 | 2004-09-28 | |
| PCT/US2005/003725 WO2006121422A2 (en) | 2004-02-06 | 2005-02-04 | Antibodies against clostridium difficile toxins and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110599T1 true HRP20110599T1 (hr) | 2011-10-31 |
Family
ID=36928722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110599T HRP20110599T1 (hr) | 2004-02-06 | 2011-08-11 | Antitijela protiv toksina clostridium difficile i njihove primjene |
Country Status (26)
| Country | Link |
|---|---|
| US (8) | US7625559B2 (de) |
| EP (3) | EP2270045B8 (de) |
| JP (3) | JP4588763B2 (de) |
| KR (3) | KR101332927B1 (de) |
| CN (1) | CN101014620B (de) |
| AT (1) | ATE512986T1 (de) |
| AU (1) | AU2005320349C1 (de) |
| BR (1) | BRPI0507433C1 (de) |
| CA (1) | CA2553946C (de) |
| CY (3) | CY1111860T1 (de) |
| DK (3) | DK2270045T3 (de) |
| ES (3) | ES2366626T3 (de) |
| HK (3) | HK1152048A1 (de) |
| HR (1) | HRP20110599T1 (de) |
| HU (3) | HUE024962T2 (de) |
| LT (2) | LT2857418T (de) |
| LU (1) | LUC00025I2 (de) |
| MX (1) | MXPA06008839A (de) |
| NO (2) | NO340300B1 (de) |
| NZ (2) | NZ580828A (de) |
| PL (3) | PL2857418T3 (de) |
| PT (3) | PT2857418T (de) |
| RS (1) | RS51908B (de) |
| SI (3) | SI1766093T1 (de) |
| WO (1) | WO2006121422A2 (de) |
| ZA (1) | ZA200606516B (de) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| AU2005320349C1 (en) * | 2004-02-06 | 2019-06-13 | E. R. Squibb & Sons, L.L.C. | Antibodies against clostridium difficile toxins and uses thereof |
| EP1782820B1 (de) * | 2004-06-28 | 2014-07-30 | Japan Science and Technology Agency | Screening-verfahren für toxin-neutralisiererndes peptid, stx2-hemmendes peptid und vero toxin-neutralisierendes mittel |
| CA2592015A1 (en) * | 2004-12-27 | 2006-07-06 | Progenics Pharmaceuticals (Nevada), Inc. | Orally deliverable and anti-toxin antibodies and methods for making and using them |
| UA96768C2 (uk) * | 2006-08-02 | 2011-12-12 | Йоганес Гутенберг-Універсітет Майнц | Лікарський засіб від lct-отруєнь |
| AU2014201846B2 (en) * | 2007-01-30 | 2016-07-07 | Epivax, Inc. | Regulatory t cell epitopes, compositions and uses thereof |
| EP2450369A1 (de) | 2007-01-30 | 2012-05-09 | Epivax, Inc. | Regulatorische t-zellen-epitopen sowie zusammensetzungen damit und anwendungen davon |
| US20080188007A1 (en) * | 2007-02-06 | 2008-08-07 | Meridian Life Science, Inc. | Fluorescent single chain antibody and its use in detection of analytes |
| CN101363867B (zh) * | 2008-05-26 | 2012-12-19 | 北京庄笛浩禾生物医学科技有限公司 | 一种艰难梭菌a、b毒素胶体金检测试纸条及其制备方法 |
| WO2009154995A2 (en) * | 2008-05-27 | 2009-12-23 | Kyowa Hakko Kirin Co., Ltd. | Interleukin 10 receptor (il-10r) antibodies and methods of use |
| DE102008029688B4 (de) * | 2008-06-24 | 2016-06-23 | Biodics Gmbh | Verfahren zum Nachweis und zur Identifikation eines varianten C. difficile Stammes in einer Probe |
| CN102365097A (zh) * | 2009-02-20 | 2012-02-29 | 卫生防护机构 | 艰难梭菌毒素的抗体 |
| US8889363B2 (en) | 2009-07-27 | 2014-11-18 | Biodics | Method for the detection and identification of a variant C. difficile strain in a sample |
| ES2589606T3 (es) * | 2009-07-27 | 2016-11-15 | Biodics Gmbh | Procedimiento para la detección y para la identificación de una cepa de C. difficile variante en una muestra |
| US20120282274A1 (en) * | 2009-11-20 | 2012-11-08 | Northshore University Health System Research Institute | Targeting of the c-terminal segment of c.difficile toxin b for improved clinical diagnosis, prevention, and treatment |
| GB0921288D0 (en) * | 2009-12-04 | 2010-01-20 | Health Prot Agency | Therapies for preventing or suppressing clostridium difficile infection |
| ES2757675T3 (es) * | 2010-04-15 | 2020-04-29 | Progenics Pharm Inc | Anticuerpos para el tratamiento de la infección y enfermedad asociada a Clostridium difficile |
| RU2630663C9 (ru) * | 2010-04-15 | 2017-11-29 | Проджиникс Фармасьютикалс, Инк. | Антитела для лечения ассоциированных с clostridium difficile инфекции и заболеваний |
| PL2753352T5 (pl) | 2010-09-03 | 2022-10-17 | Valneva Austria Gmbh | Izolowany polipeptyd białek toksyny a i toksyny b z c. difficile i jego zastosowania |
| GB201016742D0 (en) * | 2010-10-05 | 2010-11-17 | Health Prot Agency | Clostridium difficile antigens |
| CA2815888C (en) * | 2010-10-25 | 2020-06-30 | National Research Council Of Canada | Clostridium difficile-specific antibodies and uses thereof |
| US20140127215A1 (en) * | 2010-12-29 | 2014-05-08 | Cangene Corporation | Clostridium difficile antigens |
| US8906635B2 (en) | 2011-02-28 | 2014-12-09 | Northshore University Healthsystem | Methods of diagnosing Clostridium difficile infection |
| EP4365196A2 (de) | 2011-04-22 | 2024-05-08 | Wyeth LLC | Zusammensetzungen im zusammenhang mit einem mutierten clostridium-difficile-toxin und verfahren dafür |
| CA2846486C (en) * | 2011-07-12 | 2019-08-20 | Philadelphia Health & Education Corporation | Novel clostridium difficile dna vaccine |
| SG10201804809RA (en) | 2011-08-22 | 2018-07-30 | Cnj Holdings Inc | Clostridium difficile antibodies |
| PT2758432T (pt) * | 2011-09-16 | 2019-06-14 | Ucb Biopharma Sprl | Anticorpos neutralizantes contra as exotoxinas principais tcda e tcdb de clostridium difficile |
| WO2013071409A1 (en) | 2011-11-18 | 2013-05-23 | National Research Council Of Canada (Nrc) | Clostridium difficile lipoteichoic acid and uses thereof |
| WO2013084071A2 (en) | 2011-12-08 | 2013-06-13 | Novartis Ag | Clostridium difficile toxin-based vaccine |
| DE102011121238A1 (de) * | 2011-12-14 | 2013-06-20 | Universitätsklinikum Hamburg-Eppendorf | Einzeldomänen-antikörper gegen clostridium difficile toxine |
| AR089797A1 (es) | 2012-01-27 | 2014-09-17 | Merck Sharp & Dohme | Vacunas contra clostridum difficile que comprenden toxinas recombinantes |
| CN108101983A (zh) * | 2012-03-02 | 2018-06-01 | 瑞泽恩制药公司 | 艰难梭状芽孢杆菌毒素的人源抗体 |
| GB201206070D0 (en) | 2012-04-04 | 2012-05-16 | Health Prot Agency | Clostridium difficile antigens |
| JPWO2014061783A1 (ja) * | 2012-10-19 | 2016-09-05 | 株式会社イーベック | クロストリジウム・ディフィシルの毒素に特異的なヒト抗体もしくはその抗原結合性断片 |
| BR122016023101B1 (pt) * | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| WO2014085749A2 (en) * | 2012-11-28 | 2014-06-05 | Cnj Holdings, Inc. | Antibodies against clostridium difficile |
| US10160797B2 (en) | 2013-03-15 | 2018-12-25 | Sanofi Pasteur Biologics, Llc | Antibodies against Clostridium difficile toxins and methods of using the same |
| NZ713233A (en) * | 2013-04-19 | 2020-10-30 | Immuron Ltd | Methods and compositions for the treatment and/or prophylaxis of clostridium difficile associated disease |
| US9181632B1 (en) | 2013-09-09 | 2015-11-10 | Merck Sharp & Dohme Corp. | C.difficile toxin B CROP domain peptides, antibodies and complexes thereof |
| WO2015100409A2 (en) * | 2013-12-26 | 2015-07-02 | Tufts University | Methods, compositions and kits for treating a subject using a recombinant neutralizing binding protein |
| BR112016018313A8 (pt) * | 2014-02-10 | 2018-06-12 | Igm Biosciences Inc | Moléculas de ligação multiespecíficas iga |
| US20170226192A1 (en) | 2014-02-19 | 2017-08-10 | Jody Berry | Methods of modulating an immune response |
| JP2017512759A (ja) | 2014-04-10 | 2017-05-25 | オービーアイ ファーマ インコーポレイテッド | 抗体、前記抗体を産生するハイブリドーマ、前記抗体を含む薬学的組成物及びその用途 |
| WO2015184454A1 (en) * | 2014-05-30 | 2015-12-03 | Case Western Reserve University | Clostridium difficile culture medium |
| US10513552B2 (en) | 2014-06-20 | 2019-12-24 | Immunimed Inc. | Use of polyclonal antibodies against clostridium difficile for treatment of inflammatory bowel disease |
| EP2957570B1 (de) | 2014-06-20 | 2019-04-17 | Immunimed Inc. | Polyklonale antikörper gegen clostridium difficile und ihre verwendung |
| EP3271375B1 (de) * | 2015-02-19 | 2021-02-24 | Immune Biosolutions Inc. | Clostridium-difficile-toxine-a- und/oder -b-antigen und epitop-antikörper und pharmazeutische verwendungen davon |
| WO2016156474A1 (en) | 2015-03-31 | 2016-10-06 | Vhsquared Limited | Polypeptide comprising an immunoglobulin chain variable domain which binds to clostridium difficile toxin a |
| EP3277706A1 (de) | 2015-03-31 | 2018-02-07 | VHsquared Limited | Polypeptid mit immunglobulinkettenvariabler domäne mit bindung an clostridium-difficile-toxin b |
| CN105039262B (zh) * | 2015-07-10 | 2018-07-03 | 北京科兴中维生物技术有限公司 | 破伤风类毒素单克隆抗体及其应用 |
| CN116063481A (zh) | 2015-09-04 | 2023-05-05 | 普里玛托普医疗股份有限公司 | 人源化抗-cd40抗体及其用途 |
| LT3390441T (lt) | 2015-12-15 | 2021-11-10 | Gilead Sciences, Inc. | Žmogaus imunodeficito virusą neutralizuojantys antikūnai |
| WO2017189964A2 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| WO2018035407A1 (en) * | 2016-08-19 | 2018-02-22 | Enbiotix, Inc. | Bacteriophages for neutralizing toxins and methods of use thereof |
| AR112257A1 (es) | 2017-06-21 | 2019-10-09 | Gilead Sciences Inc | Anticuerpos multiespecíficos dirigidos al vih-1 gp120 y cd3 humana, composiciones que los comprende, ácido nucleico, vector y célula huésped relacionados, método para producirlos, método para detectar células que expresan gp120 y cd3, kit de anticuerpos, fragmentos de anticuerpo que se une a gp120 y método para producirlos |
| US20190324034A1 (en) * | 2018-04-19 | 2019-10-24 | First Light Biosciences, Inc. | Detection of targets |
| US20220226430A1 (en) * | 2019-05-11 | 2022-07-21 | The Texas A&M University System | Protein inhibitors of clostridium difficile toxin b |
| WO2021219786A1 (en) * | 2020-04-30 | 2021-11-04 | Gottfried Himmler | Anti-toxin secretory iga2 preparation |
| CN111499738B (zh) * | 2020-06-03 | 2022-04-05 | 郑州师范学院 | 一种抗艰难梭菌肠毒素a的抗体 |
| CN112812189B (zh) * | 2020-11-30 | 2022-05-17 | 四川大学华西医院 | 一种抗糖基转移酶a亚单位的纳米抗体及其应用 |
| CN117720651B (zh) * | 2023-12-13 | 2024-05-31 | 北京新兴四寰生物技术有限公司 | 抗艰难梭菌毒素b的单克隆抗体及其应用 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4879218A (en) | 1982-09-13 | 1989-11-07 | Virginia Tech Intellectual Properties, Inc. | Antibody for C.difficile |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (de) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimäre Rezeptoren durch Verbindung und Expression von DNS |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5332583A (en) | 1987-11-24 | 1994-07-26 | Connaught Laboratories Limited | Vaccine containing genetically-detoxified pertussis holotoxin |
| GB8727489D0 (en) | 1987-11-24 | 1987-12-23 | Connaught Lab | Detoxification of pertussis toxin |
| US5358868A (en) | 1987-11-24 | 1994-10-25 | Connaught Laboratories Limited | Genetic detoxification of pertussis toxin |
| US5221618A (en) | 1987-11-24 | 1993-06-22 | Connaught Laboratories Limited | Genetic detoxification of pertussis toxin |
| US5244657A (en) | 1987-11-24 | 1993-09-14 | Connaught Laboratories Limited | Genetic detoxification of pertussis toxin |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5736139A (en) * | 1989-10-31 | 1998-04-07 | Ochidian Pharmaceuticals, Inc. | Treatment of Clostridium difficile induced disease |
| US5919665A (en) * | 1989-10-31 | 1999-07-06 | Ophidian Pharmaceuticals, Inc. | Vaccine for clostridium botulinum neurotoxin |
| US5601823A (en) | 1989-10-31 | 1997-02-11 | Ophidian Pharmaceuticals, Inc. | Avian antitoxins to clostridium difficle toxin A |
| US5231003A (en) | 1990-05-11 | 1993-07-27 | Cambridge Bioscience Corporation | Monoclonal antibodies specific for toxin b of clostridium difficile |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| KR100272077B1 (ko) * | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| DE69224906T2 (de) | 1991-07-08 | 1998-10-29 | Univ Massachusetts | Thermotropes flüssig-kristallines segment-blockcopolymer |
| CA2125396A1 (en) * | 1991-12-10 | 1993-06-24 | Wayne A. Marasco | Reactive neutralizing human anti-gp 120 recombinant antibody, dna coding the same and use thereof |
| US5466672A (en) | 1992-12-04 | 1995-11-14 | Ophidian Pharmaceuticals, Inc. | Therapeutic use of clostridium difficile toxin A |
| EP0754225A4 (de) | 1993-04-26 | 2001-01-31 | Genpharm Int | Heterologe antikörper produzierende transgene nicht-humane tiere |
| US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
| HUT78048A (hu) | 1994-10-24 | 1999-07-28 | Ophidian Pharmaceuticals, Inc. | A C. difficile által okozott betegség kezelésére és megelőzésére szolgáló vakcina és antitoxin |
| GB9621295D0 (en) * | 1995-12-07 | 1996-11-27 | Cambridge Antibody Tech | Specific binding members,materials and methods |
| WO1998059053A1 (en) | 1997-06-20 | 1998-12-30 | Queen Mary & Westfield College | Immonogenic fragments of toxin a of clostridium difficile |
| DE19739685A1 (de) * | 1997-09-10 | 1999-03-11 | Eichel Streiber Christoph Von | Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile |
| AU754270B2 (en) * | 1997-10-20 | 2002-11-07 | Sanofi Pasteur Biologics, Llc | Passive immunization against clostridium difficile disease |
| US6733760B1 (en) | 1999-04-09 | 2004-05-11 | Techlab, Inc. | Recombinant toxin A/toxin B vaccine against Clostridium difficile |
| WO2001009187A2 (en) | 1999-07-29 | 2001-02-08 | Medarex, Inc. | Human monoclonal antibodies to her2/neu |
| CN1371416B (zh) | 1999-08-24 | 2012-10-10 | 梅达里克斯公司 | 人ctla-4抗体及其应用 |
| GB0001448D0 (en) * | 2000-01-21 | 2000-03-08 | Novartis Ag | Organic compounds |
| DE16192152T1 (de) * | 2000-05-26 | 2020-08-06 | Immunex Corporation | Verwendung von interleukin-4 rezeptor (il-4r) antikörpern und zusammensetzungen davon |
| UA81743C2 (uk) * | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
| TWI334439B (en) * | 2001-08-01 | 2010-12-11 | Centocor Inc | Anti-tnf antibodies, compositions, methods and uses |
| CA2474616A1 (en) * | 2002-01-28 | 2003-08-07 | Medarex, Inc. | Human monoclonal antibodies to prostate specific membrane antigen (psma) |
| ES2362931T3 (es) * | 2002-03-04 | 2011-07-15 | Imclone Llc | Anticuerpos humanos específicos contra kdr y usos de los mismos. |
| CN1283662C (zh) * | 2002-03-21 | 2006-11-08 | 伊莱利利公司 | 拮抗性抗hFAS配基人类抗体及其片段 |
| EP1554392A4 (de) | 2002-05-06 | 2007-08-08 | Us Gov Health & Human Serv | Identifizierung neuer neutralisierender menschlicher monoklonaler antikörper mit breiter kreuzreaktivität unter verwendung eines sequentiellen antigen-panning von phagen-display-bibliotheken |
| TWI320716B (en) * | 2002-10-14 | 2010-02-21 | Abbott Lab | Erythropoietin receptor binding antibodies |
| US7396913B2 (en) * | 2002-10-14 | 2008-07-08 | Abbott Laboratories | Erythropoietin receptor binding antibodies |
| RU2377253C2 (ru) * | 2002-12-02 | 2009-12-27 | Амген Фремонт,Инк. | Антитела, специфичные к фактору некроза опухолей, и их применение |
| EP1572736A2 (de) | 2002-12-10 | 2005-09-14 | Endocube SAS | Thap proteine als nukleare rezeptoren für chemokine und ihre rolle in der transkriptionsregulation, der zellproliferierung und der zelldifferenzierung |
| US20070003561A1 (en) * | 2003-07-08 | 2007-01-04 | Sorensen Anders P | Binding member towards pneumococcus surface adhesin a protein (psaa) |
| MXPA06005941A (es) * | 2003-12-10 | 2006-08-23 | Medarex Inc | Anticuerpos ip-10 y sus usos. |
| AU2005320349C1 (en) | 2004-02-06 | 2019-06-13 | E. R. Squibb & Sons, L.L.C. | Antibodies against clostridium difficile toxins and uses thereof |
| IT1395574B1 (it) | 2009-09-14 | 2012-10-16 | Guala Dispensing Spa | Dispositivo di erogazione |
-
2005
- 2005-02-04 AU AU2005320349A patent/AU2005320349C1/en active Active
- 2005-02-04 PT PT141945519T patent/PT2857418T/pt unknown
- 2005-02-04 HU HUE10010733A patent/HUE024962T2/en unknown
- 2005-02-04 PL PL14194551T patent/PL2857418T3/pl unknown
- 2005-02-04 CA CA2553946A patent/CA2553946C/en active Active
- 2005-02-04 KR KR1020117029761A patent/KR101332927B1/ko active IP Right Grant
- 2005-02-04 EP EP10010733.3A patent/EP2270045B8/de active Active
- 2005-02-04 US US11/051,453 patent/US7625559B2/en active Active
- 2005-02-04 EP EP05857759A patent/EP1766093B1/de active Active
- 2005-02-04 DK DK10010733.3T patent/DK2270045T3/en active
- 2005-02-04 KR KR1020067017771A patent/KR101332994B1/ko active IP Right Grant
- 2005-02-04 MX MXPA06008839A patent/MXPA06008839A/es active IP Right Grant
- 2005-02-04 PL PL05857759T patent/PL1766093T3/pl unknown
- 2005-02-04 KR KR1020127017138A patent/KR20120083534A/ko not_active Application Discontinuation
- 2005-02-04 EP EP14194551.9A patent/EP2857418B1/de active Active
- 2005-02-04 WO PCT/US2005/003725 patent/WO2006121422A2/en active Application Filing
- 2005-02-04 ES ES05857759T patent/ES2366626T3/es active Active
- 2005-02-04 NZ NZ580828A patent/NZ580828A/en unknown
- 2005-02-04 PT PT100107333T patent/PT2270045E/pt unknown
- 2005-02-04 LT LTEP14194551.9T patent/LT2857418T/lt unknown
- 2005-02-04 DK DK14194551.9T patent/DK2857418T3/en active
- 2005-02-04 PL PL10010733T patent/PL2270045T3/pl unknown
- 2005-02-04 CN CN2005800041265A patent/CN101014620B/zh active Active
- 2005-02-04 AT AT05857759T patent/ATE512986T1/de active
- 2005-02-04 SI SI200531344T patent/SI1766093T1/sl unknown
- 2005-02-04 HU HUE14194551A patent/HUE034552T2/en unknown
- 2005-02-04 PT PT05857759T patent/PT1766093E/pt unknown
- 2005-02-04 NZ NZ548821A patent/NZ548821A/en unknown
- 2005-02-04 BR BRPI0507433A patent/BRPI0507433C1/pt active IP Right Grant
- 2005-02-04 RS RS20110361A patent/RS51908B/en unknown
- 2005-02-04 DK DK05857759.4T patent/DK1766093T3/da active
- 2005-02-04 ES ES10010733.3T patent/ES2533492T3/es active Active
- 2005-02-04 JP JP2007527193A patent/JP4588763B2/ja active Active
- 2005-02-04 SI SI200532173T patent/SI2857418T1/en unknown
- 2005-02-04 SI SI200531949T patent/SI2270045T1/sl unknown
- 2005-02-04 ES ES14194551.9T patent/ES2643760T3/es active Active
-
2006
- 2006-08-04 ZA ZA2006/06516A patent/ZA200606516B/en unknown
- 2006-08-23 NO NO20063767A patent/NO340300B1/no active Protection Beyond IP Right Term
-
2007
- 2007-09-25 HK HK11105869.4A patent/HK1152048A1/xx unknown
- 2007-09-25 HK HK07110397.1A patent/HK1102287A1/xx unknown
-
2009
- 2009-07-31 US US12/533,552 patent/US8257709B2/en active Active
- 2009-07-31 US US12/533,501 patent/US8236311B2/en active Active
-
2010
- 2010-07-28 JP JP2010169364A patent/JP5319622B2/ja active Active
-
2011
- 2011-08-11 HR HR20110599T patent/HRP20110599T1/hr unknown
- 2011-09-13 CY CY20111100872T patent/CY1111860T1/el unknown
-
2012
- 2012-06-07 US US13/490,757 patent/US8609111B2/en active Active
-
2013
- 2013-02-27 JP JP2013036855A patent/JP5717300B2/ja active Active
- 2013-11-14 US US14/080,598 patent/US9217029B2/en active Active
-
2015
- 2015-09-24 HK HK15109420.4A patent/HK1208873A1/xx unknown
- 2015-10-29 US US14/926,706 patent/US20160152694A1/en not_active Abandoned
-
2017
- 2017-06-27 HU HUS1700028C patent/HUS1700028I1/hu unknown
- 2017-06-28 CY CY2017022C patent/CY2017022I1/el unknown
- 2017-07-04 LU LU00025C patent/LUC00025I2/en unknown
- 2017-07-07 NO NO2017032C patent/NO2017032I1/no unknown
- 2017-07-11 LT LTPA2017022 patent/LTC2270045I2/lt unknown
- 2017-09-21 CY CY20171101001T patent/CY1119416T1/el unknown
-
2018
- 2018-03-19 US US15/924,703 patent/US20180208643A1/en not_active Abandoned
-
2020
- 2020-09-16 US US17/022,766 patent/US20210269511A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110599T1 (hr) | Antitijela protiv toksina clostridium difficile i njihove primjene | |
| HRP20210876T1 (hr) | Anti-tmprss2 antitijela i fragmenti koji vezuju antigen | |
| CN110799539B (zh) | 抗4-1bb抗体及其制备和使用方法 | |
| HRP20120701T1 (hr) | Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1 | |
| JP2018510636A5 (de) | ||
| JP7257971B6 (ja) | 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用 | |
| RU2013125306A (ru) | Связывающие протеины, специфичные по отношению к инсулин-подобным факторам роста, и их использование | |
| CN107428832A (zh) | 抗pd‑l1抗体 | |
| RU2015142815A (ru) | Лечение рака с использованием антител, связывающихся с поверхностным grp78 | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| RU2016129113A (ru) | Антитела к pd-1 собак | |
| RU2013125459A (ru) | АНТИТЕЛА ПРОТИВ БЕЛКА РЕЦЕПТОРА c-Met | |
| JP2013523190A5 (de) | ||
| RU2012103212A (ru) | Tlr3 связывающие агенты | |
| RU2015144105A (ru) | Антитела к гепсидину и их применения | |
| WO2015191934A2 (en) | Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases | |
| JP2014529610A5 (de) | ||
| HRP20192038T1 (hr) | Protutijela receptora anti-epidermalnog faktora rasta (egfr) | |
| JPWO2019175220A5 (de) | ||
| JPWO2019175217A5 (de) | ||
| JPWO2019175216A5 (de) | ||
| JPWO2019175215A5 (de) | ||
| RU2012137380A (ru) | Моноклональные антитела к cd44, предназначенные для применения при лечении плоскоклеточной карциномы головы и шеи | |
| IL259036A (en) | asct2-specific binding molecules and their uses | |
| JPWO2019175222A5 (de) |